九安医疗(002432) - 2016 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2016 was ¥112,311,325.50, representing a 4.79% increase compared to ¥107,181,295.34 in the same period last year[7]. - The net profit attributable to shareholders was a loss of ¥14,406,786.70, an improvement of 14.59% from a loss of ¥16,867,877.16 in the previous year[7]. - The operating profit for Q1 2016 was a loss of CNY 18,983,657.43, worsening from a loss of CNY 15,793,141.21 in the previous period[38]. - Comprehensive income for Q1 2016 totaled CNY -13,961,973.66, compared to CNY -17,471,271.94 in the previous period[39]. - Basic and diluted earnings per share for Q1 2016 were both CNY -0.0387, an improvement from CNY -0.0453 in the previous period[39]. Cash Flow - The net cash flow from operating activities improved by 40.12%, reaching -¥21,795,770.73 compared to -¥36,397,102.41 in the same period last year[7]. - Total cash inflow from operating activities was 107,989,183.99 CNY, while cash outflow was 129,784,954.72 CNY, resulting in a net cash flow of -21,795,770.73 CNY[46]. - The net cash flow from investing activities was -1,192,659.55 CNY, an improvement from -3,205,503.53 CNY in the previous period[46]. - The net cash flow from financing activities was -52,011,157.63 CNY, worsening from -11,559,816.08 CNY in the previous period[47]. Assets and Liabilities - The total assets at the end of the reporting period were ¥763,528,573.03, down 6.87% from ¥819,867,228.06 at the end of the previous year[7]. - Current assets totaled CNY 443,147,364.45, down from CNY 495,431,259.29, indicating a decrease of about 10.5%[29]. - Total liabilities decreased from CNY 210,920,941.67 to CNY 168,544,260.30, a reduction of about 20.1%[31]. - The company's equity attributable to shareholders decreased from CNY 608,946,286.39 to CNY 594,984,312.73, a decline of approximately 2.3%[32]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 71,590[10]. - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, held 44.71% of the shares, totaling 166,333,302 shares[10]. - The company did not engage in any repurchase transactions during the reporting period[11]. Investments and Expenditures - Development expenditures increased by 39.04% to 11,835,916.93 due to ongoing new product development[14]. - The company has ongoing investments in development expenditures, which increased from CNY 8,512,892.98 to CNY 11,835,916.93, reflecting a growth of approximately 39.5%[30]. - Long-term equity investments declined by 32.54% to 9,294,929.17 as a result of losses from associated companies[14]. Future Outlook - The company expects a net loss of between 20,000 to 40,000 in the first half of 2016, compared to a net loss of 39,960.3 in the same period of 2015[21]. - The company is in a transition phase towards mobile internet, requiring significant investment in new product development and partnerships with medical institutions[21]. - The company is focusing on expanding its market presence and enhancing product development strategies to improve future performance[25]. Accounting and Policy Changes - There were no changes in accounting policies or corrections of accounting errors that would require restating previous years' financial data[7].